Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04686279 · ClinicalTrials.gov registry record · Phase 1
Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04686279: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT04686279 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04686279, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
ATN DREAM is an early phase-1, open label study to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of a one-dose tenofovir (TFV) medicated douche. The overall goal is to inform the design of an extended safety study of an on-demand and behaviorally congruent TFV douche to confer protection from HIV acquisition in an outpatient pre-RAI context
Interventions
- DRUG Tenofovir Douche
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2022-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04686279
The ClinicalTrials.gov registry entry for NCT04686279 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir Douche is the first listed.
NCT04686279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04686279 about?
NCT04686279 is a clinical study titled "Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)". ATN DREAM is an early phase-1, open label study to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of a one-dose tenofovir (TFV) medicated douche. The overall goal is to inform the design of an extended safety study of an on-demand and behaviorally congruent TFV d...
What is the current status of trial NCT04686279?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-04-01. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT04686279?
The interventions under investigation include: Tenofovir Douche (DRUG).
Who is sponsoring clinical trial NCT04686279?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.